| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Cisplatin | GDSC1000 | pan-cancer | AAC | -0.016 | 0.6 |
| mRNA | lovastatin | CTRPv2 | pan-cancer | AAC | -0.017 | 0.6 |
| mRNA | Doxorubicin | FIMM | pan-cancer | AAC | 0.078 | 0.6 |
| mRNA | CAL-101 | CTRPv2 | pan-cancer | AAC | -0.016 | 0.6 |
| mRNA | VNLG/124 | GDSC1000 | pan-cancer | AAC | 0.015 | 0.7 |
| mRNA | vorapaxar | CTRPv2 | pan-cancer | AAC | 0.017 | 0.7 |
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | -0.036 | 0.7 |
| mRNA | semagacestat | CTRPv2 | pan-cancer | AAC | 0.016 | 0.7 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | 0.02 | 0.7 |
| mRNA | CIL55A | CTRPv2 | pan-cancer | AAC | 0.022 | 0.7 |